XML 28 R7.htm IDEA: XBRL DOCUMENT
v3.20.4

Business and basis of consolidation | 12 Months Ended
--- | ---
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements And Unusual Or Infrequent Items Disclosure [Abstract] |
Business, basis of presentation, COVID-19 update, and CARES Act |
1. | Business, basis of presentation, COVID-19 update, and CARES Act
Description of the Business Orthofix Medical Inc. and its subsidiaries (the “Company”) is a global medical device and biologics company with a spine and extremities focus. The Company’s mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patients’ lives. Headquartered in Lewisville, Texas, the Company has two reporting segments: Global Spine and Global Extremities. Orthofix spine and orthopedic extremities products are distributed in over 70 countries via the Company's sales representatives and distributors. Basis of Presentation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Information on our accounting policies and methods used in the preparation of our consolidated financial statements are included, where applicable, in the respective footnotes that follow.
Footnote |  | Footnote Reference
Business, basis of presentation, COVID-19 update, and CARES Act |  | 1
Significant accounting policies |  | 2
Recently adopted accounting standards and recently issued accounting pronouncements |  | 3
Acquisitions |  | 4
Inventories |  | 5
Property, plant and equipment |  | 6
Intangible assets |  | 7
Goodwill |  | 8
Leases |  | 9
Other current liabilities |  | 10
Long-term debt |  | 11
Fair value measurements and investments |  | 12
Commitments and contingencies |  | 13
Shareholders' equity |  | 14
Revenue recognition and accounts receivable |  | 15
Business segment information |  | 16
Acquisition-related amortization and remeasurement |  | 17
Share-based compensation |  | 18
Defined contribution plans and deferred compensation |  | 19
Income taxes |  | 20
Earnings per share |  | 21
Subsequent events |  | 22
COVID-19 Update The global Coronavirus Disease 2019 ("COVID-19") pandemic has significantly affected the Company’s patients, communities, employees and business operations. The pandemic has led to the cancellation or deferral of elective surgeries and procedures within certain hospitals, ambulatory surgery centers, and other medical facilities; restrictions on travel; the implementation of physical distancing measures; and the temporary or permanent closure of certain businesses. In addition, broad economic factors resulting from the pandemic, including increased unemployment rates and reduced consumer spending, are affecting the Company’s patients and partners. These circumstances have negatively affected the Company’s net sales, particularly during the period from March 2020 through May 2020, when elective surgery restrictions were most pronounced, though these effects remain ongoing in certain geographical areas. However, the Company remains focused on protecting the health and wellbeing of its employees, partners, patients, and the communities in which it operates while assuring the continuity of its business operations. The Company's consolidated financial statements reflect estimates and assumptions made by management that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting periods presented. At this time, the future trajectory of the COVID-19 pandemic remains uncertain, both in the U.S. and in other markets. Although the Company anticipates that vaccines will be widely distributed in the future, the timing and efficacy of such vaccines are uncertain. Given these various uncertainties, it is unclear the extent to which lingering slowdowns in elective procedures will affect the Company’s business into 2021 and beyond. The expected effects of COVID-19 on the Company’s business will depend on various factors including (i) the magnitude and length of additional case waves, (ii) the distribution, efficacy, and public acceptance of COVID-19 vaccines (iii) the comfort level of patients in returning to clinics and hospitals, (iv) the extent to which localized elective surgery shutdowns occur, (v) the unemployment rate’s effect on potential patients lacking medical insurance coverage, and (vi) general hospital capacity constraints occurring because of the need to treat COVID-19 patients. In addition, while the Company has not seen such effects to date, risk remains that COVID-19 could have material negative effects on contractual counterparties, leading to supply chain disruptions or counterparty payment defaults and bankruptcies (including bankruptcies to hospital systems that significantly rely on revenue from elective surgeries). These matters are also described in Part I, Item 1A of this Form 10-K under the heading Risk Factors. Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) On March 27, 2020, the President of the United States signed the CARES Act into federal law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, included provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no impact to the Company’s income tax benefit reported within the consolidated statements of operations for the year ended December 31, 2020. The CARES Act has provided financial relief to the Company through other various programs, which are each described in further detail below. In April 2020, the Company received $13.9 million in funds from the Centers for Medicare & Medicaid Services (“CMS”) Accelerated and Advance Payment Program. For discussion of the Company’s accounting for these funds, see Note 15. The Company also automatically received, as a durable medical equipment provider, without request, $4.7 million in funds from the U.S. Department of Health and Human Services in April 2020 as part of the Provider Relief Fund. Upon review of the qualifying criteria required to retain the funding, which primarily relate to lost revenues or the incurrence of expenses attributable to COVID-19, it was determined that the Company met the criteria to retain the funds received. As such, the Company recognized other income of $4.7 million related to this in-substance grant for the year ended December 31, 2020. In addition, as part of the CARES Act, the Company was permitted to defer all employer social security payroll tax payments for the remainder of the 2020 calendar year, such that 50% of the taxes are deferred until December 31, 2021, with the remaining 50% deferred until December 31, 2022. As of December 31, 2020, the Company has deferred $0.6 million associated with this program, all of which is classified within other current liabilities. This deferred balance was subsequently repaid in the first quarter of 2021.

X
- Definition Organization consolidation and presentation of financial statements and unusual or infrequent items disclosure. + References No definition available. + Details
Name: | ofix_OrganizationConsolidationAndPresentationOfFinancialStatementsAndUnusualOrInfrequentItemsDisclosureAbstract
Namespace Prefix: | ofix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Organization consolidation and presentation of financial statements and unusual or infrequent items disclosure. + References No definition available. + Details
Name: | ofix_OrganizationConsolidationAndPresentationOfFinancialStatementsAndUnusualOrInfrequentItemsDisclosureTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration